Point estimation for adaptive trial designs II: Practical considerations and guidance

URN to cite this document:: urn:nbn:de:bvb:355-epub-758761
DOI to cite this document:: 10.5283/epub.75876

Robertson, David S. ; Choodari‐Oskooei, Babak ; Dimairo, Munya

; Flight, Laura ; Pallmann, Philip

; Jaki, Thomas

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 18 Mar 2025 10:06

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

In adaptive clinical trials, the conventional end-of-trial point estimate of a treatment effect is prone to bias, that is, a systematic tendency to deviate from its true value. As stated in recent FDA guidance on adaptive designs, it is desirable to report estimates of treatment effects that reduce or remove this bias. However, it may be unclear which of the available estimators are preferable, ...